BETH EMAMI: Open Payments
NPI 1417986365 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$506 in 20 payments from 7 companies in 2025. Trend: 2023 $1,443 · 2024 $359 · 2025 $506
Food & beverage: $406Education: $100
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 7 | $162 |
| Astellas Pharma US Inc | 3 | $138 |
| ABBVIE INC. | 3 | $78 |
| MILLICENT US INC | 4 | $62 |
| 180 Medical, Inc. | 1 | $29 |
| MAYNE PHARMA COMMERCIAL LLC | 1 | $21 |
| Medtronic, Inc. | 1 | $18 |
Products named: GEMTESA, BOTOX, INTRAROSA, Veozah, GENTLECATH, ALTAVIVA, FEMLYV.
Industry payments across MD — which companies pay providers there.
